Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.

Weight loss meds confer minimal impact on cardiometabolic risk

Roshini Claire Anthony
02 Feb 2018

The use of weight loss medications for at least 1 year did little to improve cardiometabolic risk factors in obese adults, according to a systematic review and meta-analysis.

“Though FDA-approved pharmacological agents for long-term treatment of obesity result in significant weight loss … they appear to have modest impact on modifying key cardiometabolic risk-factors, even one year after therapy,” said the researchers.

“Most drugs were associated with improvements in waist circumference, but only marginal improvements in serum cholesterol profile and [blood pressure],” they said.

Researchers analysed 28 randomized controlled trials which compared the effects of ≥1 year of treatment with FDA-approved weight loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) with placebo or other active agents in obese adults (n=29,018, median age 46 years, median baseline BMI 36.1 kg/m2, 77 percent female).

With regards to effect of medication on cardiometabolic risk factors, a standardized mean difference (SMD) of <0.2 suggested minimal benefit, 0.2–0.4 suggested modest benefit, 0.4–0.7 suggested moderate benefit, and >0.7 suggested a large benefit.

Overall, weight loss medications were associated with modest reductions in fasting blood glucose levels (weighted mean difference [WMD], -4.0 mg/dL, 95 percent confidence interval [CI], -4.4 to -3.6; SMD, -0.27) and waist circumference (WMD, -3.3 cm, 95 percent CI, -3.5 to -3.1; SMD, -0.36) compared with placebo. [Gastroenterology 2018;doi:10.1053/j.gastro.2017.12.024]

Conversely, weight loss medications had little impact on systolic or diastolic blood pressure or cholesterol levels compared with placebo, though the impact differed by medication.

“The effect of individual drugs varied substantially and closely followed their mechanism of action,” the researchers said.

For instance, compared with placebo, the antidiabetic drug liraglutide was associated with a moderate reduction in fasting blood glucose (WMD, -15.6 mg/dL), HbA1c (WMD, -0.5 percent), and waist circumference (-4 cm) but had a minimal effect on blood pressure and cholesterol levels.

Compared with placebo, the lipase inhibitor orlistat was associated with reductions in HbA1c (WMD, -0.4 percent) and LDL- (WMD, -8.7 mg/dL) and HDL-cholesterol levels (WMD, -1.1 mg/dL).

The use of phentermine-topiramate was associated with reductions in waist circumference, fasting blood glucose, HbA1c, and systolic blood pressure levels but had a minimal impact on cholesterol levels, while naltrexone-bupropion was associated with an increase in HDL-cholesterol but just a minimal impact on fasting blood glucose and waist circumference.

None of the medications improved all cardiometabolic risk factors and no medications proved superior to the others.

According to the researchers, these findings contradict those obtained with other weight-loss therapies, notably bariatric surgery which has been associated with improvements in cardiometabolic risk factors in both diabetics and nondiabetics. [JAMA Surg 2014;149:716-726, Obes Surg 2012;22:1723-1729]

“This likely represents a combination of greater magnitude of weight loss with bariatric surgery as compared with pharmacotherapy, and neurohormonal changes secondary to bariatric surgery, such as increases in incretin or satiety hormones, and improvement in biochemical, inflammatory, and oxidative profiles,” they said.

The researchers acknowledged that potential between-study heterogeneity and the use of trials that mostly compared an active weight loss drug against placebo may have impacted the findings. Most studies included in the meta-analysis also did not exceed a 1-year treatment period and studies with longer follow-up periods may better establish long-term cardiovascular risk and benefit of weight loss medications, they said. 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.